NeuroVia Closes Series A Financing Round of $14M to Develop Novel Treatment Option for X-ALD Disease
CAMBRIDGE, Mass.--(BUSINESS WIRE)--NeuroVia, Inc., a biopharmaceutical company focused on developing innovative therapies for rare genetic neurological diseases, announced the closing of a Series A ...
DEAR DR. ROACH: I’m a 55-year-old mother of three daughters. I found out through genetic testing that I am a carrier for adrenoleukodystrophy. My middle daughter also is a carrier. She has three ...
Hosted on MSN
The Right Chemistry: Lorenzo's Oil contributed to the treatment of a devastating disease
ALD is the result of very long-chain saturated fatty acids containing more than 22 carbons that build up in blood plasma. These fatty acids are normally produced from dietary shorter-chain fatty acids ...
Viking Therapeutics Inc.’s stock rose 1.4% in premarket trade Wednesday, after the biotech reported positive data from an early-stage trial of a treatment for the rare, and often fatal, metabolic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results